Humanigen Forum: Community User: Rothschild123

Noch bissl… und dann bin ich wieder im Plus 🥳🥳🥳

7,52$ 😋

Something is in the air 🤩

Langsam läuft es...

Ja denke wir sind bald endlich wieder 2 Stellig 👍👍👍

https://ir.humanigen.com/English/news/news-details/2021/European-Commission-Selects-Humanigens-Lenzilumab-as-One-of-the-10-Most-Promising-Treatments-for-COVID-19-4346dba5c/default.aspx

Wird unterstützt!

Hoffentlich bald wieder 15 und mehr 🤞

👍

Endlich geht es in die richtige Richtung

🥳🥳🥳

Na das ist doch schonmal eine gute Nachricht 😁

Appointment of Directors On October 19, 2021, the Board of Directors (the “Board”) of Humanigen, Inc. (the “Company”) increased the size of the Board from five to seven members and added John A. Hohneker, MD, and Y. Kevin Xie, PhD, to fill these newly-created directorships, effective immediately. Effective immediately following the filing of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2021, Dr. Hohneker will become a member of both the Compensation Committee and the Nominating and Corporate Governance Committee, and Dr. Xie will chair the Audit Committee and become a member of the Compensation Committee of the Company’s Board. Each of Drs. Hohneker and Xie will participate in the Company’s customary non-employee director compensation program, including a one-time option grant to purchase shares of common stock upon joining the Board, and quarterly retainer payments for their future Board and committee service.

Zwei neue Boardmitglieder

Irgendwas neues?

BURLINGAME, Calif.--(BUSINESS WIRE)-- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced that a manuscript describing its budget impact model for the treatment of patients hospitalized with COVID-19 is available on medRxiv (link). These results highlight the value of selecting the right treatment for the right hospitalized patients during this time of unprecedented pressure on health systems. The cost to care for a COVID-19 patient in the ICU can significantly exceed $100,000 and average costs for patients on invasive mechanical ventilation in ICU amount to $78,245 per patient.1 Lenzilumab is an investigational product and is not currently authorized or approved in any country.